Our clinical success would be huge since Multikine would be on course to become the recommended first-line treatment for head and neck cancer. From there, we could hopefully prove that Multikine is likely to work against other solid tumors as well.
Our ultimate goal in development is to provide patients and physicians with a new and better way of fighting cancer. We believe that the key to doing so lies in our immune system. Dendreon's prostate cancer vaccine recently established that this is possible. Their success is even more impressive because they focused on late-stage cancer patients. We believe that Multikine should have an even greater chance of success because we focus on patients not yet treated for their cancer. Their immune system is still intact, except in the area of the tumor, and their lymphatics have not yet been cut, meaning that they can still deliver immune cells from the local lymph nodes to the tumor.
From here on there is only one thing to do. We will launch the Phase III study as quickly as possible. Success would be phenomenal, and we anticipate that it should enable rapid approval around the world.
We thank you for your continued support.
Chief Executive Officer
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected.
|SOURCE CEL-SCI Corporation|
Copyright©2009 PR Newswire.
All rights reserved